Vinay Bhaskar

Summary

Affiliation: Protein Design Labs
Country: USA

Publications

  1. ncbi Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits
    Vinay Bhaskar
    PDL BioPharma, Inc, 34801 Campus Drive, Fremont, CA 94555, USA
    Invest New Drugs 26:7-12. 2008
  2. ncbi A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo
    Vinay Bhaskar
    Department of Research, PDL BioPharma, Inc, Fremont, CA 94555, USA
    J Transl Med 5:61. 2007
  3. ncbi Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer
    Daniel E H Afar
    Protein Design Labs, Inc, 34801 Campus Drive, Fremont, CA 94555, USA
    Mol Cancer Ther 3:921-32. 2004
  4. ncbi E-selectin up-regulation allows for targeted drug delivery in prostate cancer
    Vinay Bhaskar
    Protein Design Labs, Inc, 34801 Campus Drive, Fremont, CA 94555, USA
    Cancer Res 63:6387-94. 2003
  5. ncbi Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent
    Vanitha Ramakrishnan
    PDL Biopharma Inc, Fremont CA 94555, USA
    J Exp Ther Oncol 5:273-86. 2006
  6. ncbi The MADF-BESS domain factor Dip3 potentiates synergistic activation by Dorsal and Twist
    Vinay Bhaskar
    Department of Chemistry and Biochemistry, University of California Los Angeles, 607 Charles E Young Drive East, Los Angeles, CA 90095 1569, USA
    Gene 299:173-84. 2002
  7. ncbi Conjugation of Smt3 to dorsal may potentiate the Drosophila immune response
    Vinay Bhaskar
    Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California 90095 1569, USA
    Mol Cell Biol 22:492-504. 2002
  8. ncbi Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target
    Kenjiro Sawada
    Department of Obstetrics and Gynecology Section of Gynecologic Oncology, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 68:2329-39. 2008

Collaborators

Detail Information

Publications8

  1. ncbi Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits
    Vinay Bhaskar
    PDL BioPharma, Inc, 34801 Campus Drive, Fremont, CA 94555, USA
    Invest New Drugs 26:7-12. 2008
    ..This effect was found to correlate with decreased blood vessel density within these tumors. These results support the use of volociximab in the intervention of malignant disease...
  2. ncbi A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo
    Vinay Bhaskar
    Department of Research, PDL BioPharma, Inc, Fremont, CA 94555, USA
    J Transl Med 5:61. 2007
    ....
  3. ncbi Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer
    Daniel E H Afar
    Protein Design Labs, Inc, 34801 Campus Drive, Fremont, CA 94555, USA
    Mol Cancer Ther 3:921-32. 2004
    ..These data support the further evaluation and clinical testing of huPr1-vcMMAE as a novel therapeutic for the treatment of metastatic and hormone-resistant prostate cancer...
  4. ncbi E-selectin up-regulation allows for targeted drug delivery in prostate cancer
    Vinay Bhaskar
    Protein Design Labs, Inc, 34801 Campus Drive, Fremont, CA 94555, USA
    Cancer Res 63:6387-94. 2003
    ..These findings demonstrate that an E-selectin-targeting ADC has potential as a prostate cancer therapy and validates a genomics-based paradigm for the identification of cancer-specific antigens suitable for targeted therapy...
  5. ncbi Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent
    Vanitha Ramakrishnan
    PDL Biopharma Inc, Fremont CA 94555, USA
    J Exp Ther Oncol 5:273-86. 2006
    ..Volociximab and F200 were potent inhibitors of neovessel formation in this model. These data demonstrate that volociximab has therapeutic potential in diseases in which new vessel formation is a component of the pathology...
  6. ncbi The MADF-BESS domain factor Dip3 potentiates synergistic activation by Dorsal and Twist
    Vinay Bhaskar
    Department of Chemistry and Biochemistry, University of California Los Angeles, 607 Charles E Young Drive East, Los Angeles, CA 90095 1569, USA
    Gene 299:173-84. 2002
    ..We assess the possibility that the MADF and BESS domains are related to the SANT domain, a well-characterized motif found in many transcriptional regulators and coregulators...
  7. ncbi Conjugation of Smt3 to dorsal may potentiate the Drosophila immune response
    Vinay Bhaskar
    Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California 90095 1569, USA
    Mol Cell Biol 22:492-504. 2002
    ..We find that the conjugation machinery is required for lipopolysaccharide-induced expression of antimicrobial peptides in cultured cells and larvae, suggesting that Smt3 regulates Dorsal function in vivo...
  8. ncbi Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target
    Kenjiro Sawada
    Department of Obstetrics and Gynecology Section of Gynecologic Oncology, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 68:2329-39. 2008
    ..Targeting this integrin could be a promising therapy for a subset of ovarian cancer patients...